Grifols (GRFS) Projected to Post Earnings on Monday

Grifols (NASDAQ:GRFS) is anticipated to post its Q1 2025 quarterly earnings results on Monday, May 12th. Analysts expect Grifols to post earnings of $0.16 per share and revenue of $1.72 billion for the quarter.

Grifols Trading Down 2.1 %

Shares of GRFS opened at $7.15 on Friday. Grifols has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The company has a market capitalization of $4.92 billion, a PE ratio of 6.11 and a beta of 0.44. The stock has a fifty day moving average of $7.34 and a two-hundred day moving average of $7.66. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.